Bayer HealthCare to storm birth control market

Published: 2007-09-18 06:59:00

Updated: 2007-09-18 06:59:00

The domestic sales of Bayer HealthCare's birth control products grew 13 percent last year, driven by the strength of Myvlar, Minivlar and Postinor-1. But Bayer HealthCare is not stagnating.

Approved by the Korea Food and Drug Administration this month, Yasmin, a new contraceptive pill, which i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK